P
PaloBiofarma
A company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation
About PaloBiofarma
Developer of drugs intended to cure diseases based on the modulation of adenosine receptors. The company focuses to discover the first marketed drug based on a selective adenosine receptor modulator leveraging medicinal chemistry and in vitro pharmacology of adenosine, enabling doctors to focus on the treatment of advanced prostate cancer. Keywords: Pharmaceuticals and Biotechnology, Adenosine Pharmaceutical, Adenosine Receptor, Cancer Therapy, Cancer Treatment, Clinical Development, Medical Services.
Source: Dealroom company dataAt a glance
- Founded
- 2006
- Headquarters
- Noáin (Valle de Elorz)/Noain (Elortzibar), Spain
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Inveready
Fitalent
European Innovation Council
Series A2 investors entered at this stage
Sodena
Foundation for Prader-Willi Syndrome Research
Series B and later1 investor entered at this stage
Asabys Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PaloBiofarma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PaloBiofarma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.